Abstract: The invention provides a CRISPR-dCas/Cas protein derivative or CRISPR-dCas/Cas protein derivative set derived from a CRISPR-dCas (dead Cas) protein or a CRISPR-Cas protein, as well as a polynucleotide encoding the same, a vector comprising the polynucleotide, a transformant transformed by the vector, a carrier for purifying a target RNA, a method for purifying a target RNA, a method for analyzing an intracellular environment, and a prophylactic or therapeutic agent.

Abstract: A hydraulic excavator specifies acceleration data being operation data in an acceleration period of a manipulation target and deceleration data being operation data in a deceleration period of the manipulation target among operation data, calculates, on the basis of the acceleration data and acceleration evaluation data, an acceleration evaluation value indicating a skill of an operator in the acceleration period, calculates, on the basis of the deceleration data and deceleration evaluation data, a deceleration evaluation value indicating a skill of the operator in the deceleration period, determines, on the basis of the acceleration evaluation value and the deceleration evaluation value, a manipulation type of the operator, and outputs support information associated with the manipulation type.

Abstract: [Object] To provide a novel examination method for a cancer treatment effect, screening method for a peptide for a cancer vaccine, and peptide and composition for inducing an immune response against cancer. [Solving Means] Provided are an examination method for a cancer treatment effect and a screening method for a peptide for a cancer vaccine each including detecting an antibody against a cancer/testis antigen or an anti-p53 antibody in a sample. It is suitable that an anti-XAGE1 antibody (IgG and/or IgA) be detected, or an anti-NY-ESO-1 antibody (IgG) be detected. Also provided are a novel peptide and novel composition for inducing immune responses against cancer.

Abstract: Disclosed is a method for assisting prediction of onset of cerebral infarction, based on the number of red blood cells contained in a blood sample collected from a subject, comprising the steps of: calculating an exponent value for the prediction from a first measured value indicating red blood cell count measured by electrical resistance measurement method and a second measured value indicating red blood cell count measured by optical measurement method, comparing the exponent value with a reference range, and suggesting that the subject develops cerebral infarction when the exponent value is outside the reference range.

Abstract: A muscle relaxation monitoring apparatus includes: a stimulating circuit that stimulates a nerve of a living body; a signal detecting circuit that detects an electric signal generated by a muscle reacting to the stimulation performed by the stimulating circuit; a reaction time calculating circuit that calculates a reaction time which elapses from the stimulation of the nerve by the stimulating circuit until the electric signal is detected by the signal detecting circuit; and a relaxation degree determining circuit that determines a muscle relaxation degree of the living body based on the length of the reaction time calculated by the reaction time calculating circuit.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: The present disclosure provides a pharmaceutical composition including biocompatible particles containing a sugar derivative, wherein the biocompatible particles contain a lactic acid-glycolic acid copolymer. The pharmaceutical composition may be used in combination with an anticancer drug.

Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Abstract: This fixture for securing a bar for funnel chest correction to a chest of a patient, includes: a base member having a length that allows the base member to extend across a plurality of ribs; a pressing member configured to be overlaid on the base member; a protrusion formed on an upper face of the base member; a plurality of screw holes formed in the base member; a plurality of holes formed in the pressing member at positions corresponding to the respective screw holes; and a plurality of screws. The pressing member is overlaid on the base member in a state where two bars are respectively disposed on both sides of the protrusion, and a screw is screwed into any of the screw holes on each of both sides of the protrusion, whereby the two bars are fixed by being sandwiched by the base member and the pressing member.

Abstract: The present invention provides a method for measuring senescence of a test subject, including a step of measuring a level of taurine modification of mitochondrial tRNALeu(UUR) in a biological sample isolated from a test subject, by a reverse transcription reaction from a primer with the tRNALeu(UUR) as a template. In addition, the present invention also provides a senescence determining drug containing a primer containing a base sequence consisting of 10-25 bases and complementary to the mitochondrial tRNALeu(UUR). Furthermore, the present invention also provides a senescence determining kit containing a primer containing a base sequence consisting of 10-25 bases and complementary to the mitochondrial tRNALeu(UUR) and a reverse transcriptase. Moreover, the present invention also provides an agent for improving a taurine modification rate of mitochondrial tRNALeu(UUR), containing taurine as an active ingredient.

Abstract: Disclosed is a method for assisting prediction of onset of cerebral infarction, based on the number of red blood cells contained in a blood sample collected from a subject, comprising the steps of: calculating an exponent value for the prediction from a first measured value indicating red blood cell count measured by electrical resistance measurement method and a second measured value indicating red blood cell count measured by optical measurement method, comparing the exponent value with a reference range, and suggesting that the subject develops cerebral infarction when the exponent value is outside the reference range.

Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.